Host: |
Goat |
Applications: |
Pep-ELISA/WB |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Goat polyclonal antibody anti-CD40-Isoform 1 (Internal) is suitable for use in ELISA and Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
Concentration: |
0.5 mg/mL |
Dilution Range: |
WB-1-3µg/mlELISA-antibody detection limit dilution 1:128000. |
Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
Gene Symbol: |
CD40 |
Gene ID: |
958 |
Uniprot ID: |
TNR5_HUMAN |
Immunogen Region: |
Internal |
Accession Number: |
NP_001241.1 |
Specificity: |
This antibody is expected to recognize isoform 1 (NP_001241.1) only. |
Immunogen Sequence: |
PQEINFPDDLPGSN |
Function | Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. |
Protein Name | Tumor Necrosis Factor Receptor Superfamily Member 5B-Cell Surface Antigen Cd40Bp50Cd40l ReceptorCdw40Cd Antigen Cd40 |
Database Links | Reactome: R-HSA-198933 P25942-1Reactome: R-HSA-5668541 P25942-1Reactome: R-HSA-5676594 P25942-1 |
Cellular Localisation | Isoform I: Cell MembraneSingle-Pass Type I Membrane ProteinIsoform Ii: Secreted |
Alternative Antibody Names | Anti-Tumor Necrosis Factor Receptor Superfamily Member 5 antibodyAnti-B-Cell Surface Antigen Cd40 antibodyAnti-Bp50 antibodyAnti-Cd40l Receptor antibodyAnti-Cdw40 antibodyAnti-Cd Antigen Cd40 antibodyAnti-CD40 antibodyAnti-TNFRSF5 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance